Circulating Tumor DNA (CtDNA) Methylation Market Expected to Grow at 13.2% CAGR Through 2029: Industry Forecast

 Unlock 30% Off Global Market Reports Using Code ONLINE30 — Stay Informed on Trade Policies, Market Growth, and Key Disruptors

 

 What Are the Key Factors Driving Circulating Tumor DNA (CtDNA) Methylation Market Size and Growth?
 The circulating tumor DNA (CtDNA) methylation market size has grown rapidly in recent years. It will grow from $1.30 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to the rising number of clinical studies on ctDNA methylation, rising adoption of precision medicine strategies, increasing use of biomarkers for prognosis, increasing publication of research supporting ctDNA methylation applications, and increasing implementation of advanced lab automation.
 
 The circulating tumor DNA (CtDNA) methylation market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to an increase in point-of-care ctDNA testing solutions, an increase in telemedicine adoption supporting remote diagnostics, a rise in global awareness about epigenetic biomarkers, an increase in cross-industry partnerships, and an increase in collaborations between research institutes and diagnostic companies. Major trends in the forecast period include integration of bioinformatics for methylation profiling, advancement in treatment response monitoring, innovation in population-level screening programs, integration of automated sample processing systems, and innovation in targeted therapy guidance.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28167&type=smp
  
 Who Are the Major Contributors to the Circulating Tumor DNA (CtDNA) Methylation Market Growth?
 The increasing prevalence of cancer is expected to drive the growth of the circulating tumor DNA (ctDNA) methylation market going forward. The prevalence of cancer is rising due to aging populations and lifestyle-related risk factors, including poor diet, smoking, and physical inactivity, which increase the risk of genetic mutations and tumor development. Circulating tumor DNA (ctDNA) methylation assays aid in early, non-invasive cancer detection, allow for accurate monitoring of disease progression, and help guide personalized treatment decisions, enabling timely and precise clinical interventions. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, the number of cancer survivors in the United States is expected to increase from 18.1 million in 2022 to 26 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the ctDNA methylation market.
 
 How Is the Circulating Tumor DNA (CtDNA) Methylation Market Divided by Type and Application?
 The circulating tumor dna (CtDNA) methylation market covered in this report is segmented as
 
 1) By Product Type: Reagents And Kits, Instrumentations, Software And Bioinformatics Solutions, Services
 2) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, Other Technologies
 3) By Sample Type: Blood Samples, Urine Samples, Saliva Samples, Tissue Samples, Other Samples
 4) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications
 5) By End-User: Hospitals And Clinics, Research Laboratories, Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies, Academic Institutions
 
 Subsegments:
 1) By Reagents And Kits: Cell Free DNA Extraction Kits, Bisulfite Conversion Kits, Methylation Detection Kits, Library Preparation Kits, Targeted Enrichment Kits
 2) By Instrumentations: Sequencers, Real Time Polymerase Chain Reaction Systems, Digital Polymerase Chain Reaction Systems, Microarray Scanners, Droplet Digital Polymerase Chain Reaction Systems
 3) By Software And Bioinformatics Solutions: Data Analysis Software, Methylation Pattern Interpretation Software, Genomic Visualization Tools, Pipeline Automation Software, Clinical Reporting Software
 4) By Services: Sample Processing Services, Sequencing Services, Bioinformatics Analysis Services, Clinical Trial Support Services, Consultation And Training Services
 
 Which Trends Are Expected to Redefine the Circulating Tumor DNA (CtDNA) Methylation Market Landscape?
 Major companies operating in the circulating tumor DNA (ctDNA) methylation market are focusing on developing multi-cancer early detection (MCED) blood tests that analyze cancer-specific methylation patterns in ctDNA, allowing for early, non-invasive detection of multiple cancer types. MCED tests help improve patient outcomes by detecting unique methylation signatures, enabling timely intervention and guiding more precise clinical decisions. For instance, in September 2025, Exact Sciences Corporation, a US-based molecular diagnostics company, launched Cancerguard, a multi-cancer early detection blood test integrating ctDNA methylation analysis. Cancerguard identifies unique methylation signatures across more than 50 cancer types, enabling highly sensitive and non-invasive detection, providing actionable insights for clinicians, and supporting ongoing monitoring and treatment decisions. This launch represents a significant step toward early intervention and improved survival rates through precision cancer care.
 
 Who Are the Emerging Players in the Circulating Tumor DNA (CtDNA) Methylation Market?
 Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled.
 
 Get the full circulating tumor dna (ctdna) methylation market report here:
 https://www.thebusinessresearchcompany.com/report/circulating-tumor-dna-ctdna-methylation-global-market-report
 
 How Is Regional Performance Expected to Affect Circulating Tumor DNA (CtDNA) Methylation Market Growth?
 North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in circulating tumor DNA (ctDNA) methylation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company